The FDA had asked Biogen and Sage Therapeutics to provide more clinical data supporting Zurzuvae in major depressive disorder. Citing the time and expense of additional clinical trials, the partners decided against further development in this indication The post Biogen, Sage Therapeutics Drop Plans to Develop Partnered Drug in Major Depressive Disorder appeared first on…
Now is a great time for employers to consider the impact GI health has on workplace equity and take steps to ensure they’re doing what they can to create an equitable workplace The post Gut Health Can Be a Workplace Equity Issue. Here’s How HR Leaders Can Prevent That appeared first on MedCity News.
This policy watch examines the impact of federal staff cuts and HHS restructuring on the nation’s HIV response.
Today’s patients want and deserve a more efficient and high-tech experience and the next generation of providers are no different. These upgrades can improve our productivity and enhance the quality of our patients’ lives. The post Disrupting Legacy Systems: Preparing for the Next Generation of Health Tech appeared first on MedCity News.
Remodel Health received $100 million in funding from Oak HC/FT and Hercules Capital. The post Remodel Health Secures Over $100M to Fuel Expansion in the ICHRA Market appeared first on MedCity News.
You can provide the best care possible inside the four walls of your hospital, but if your patients can’t afford their prescriptions after you discharge them, the system isn’t working. The post The Cost of Medication Non-Adherence — How Hospitals Can Close the Gap through Better Communication appeared first on MedCity News.
During a recent panel discussion, three healthcare experts discussed reasons why value-based care is struggling to reach scale. The post Value-Based Care Is a Four Layer Cake — Why Do We Only Focus on The Icing? appeared first on MedCity News.
Join industry leaders to explore how advanced technologies like RFID, AI, EMR, and ERP systems are transforming hospitals into connected ecosystems that enhance efficiency, streamline workflows, and improve patient outcomes.
Kailera Therapeutics licensed its portfolio of metabolic disorder drugs from Hengrui. The most advanced program has results from a Phase 2 test in China suggesting it could be competitive with other medications that target the GLP-1 and GIP receptors to trigger weight loss. The post Metabolic Meds Biotech Kailera Launches With $400M for Next-Generation Weight-Loss…
PLEASANTVILLE, Iowa — Zach Mecham has heard politicians demand that Medicaid recipients work or lose their benefits. He also has run into a jumble of Medicaid rules that effectively prevent many people with disabilities from holding full-time jobs. “Which is it? Do you want us to work or not?” he said. Mecham, 31, relies on…